CJC-1295 + Ipamorelin GH Combination
Combination evidence: No published data on combination
Last reviewed April 20, 2026
Constituent peptides
Proposed mechanism of synergy
The theoretical rationale for combining CJC-1295 (a GHRH analog acting at pituitary GHRH receptors) with ipamorelin (a ghrelin/GHS-R1a agonist acting at a distinct receptor) is that the two agonists target different receptor pathways driving growth hormone release. In principle, pairing them could produce additive pulsatile GH elevation larger than either agent alone. This is a mechanism-based hypothesis, not a tested combination.
No published randomized controlled trial has evaluated this specific combination in humans. The rationale is extrapolated from Phase 1 pharmacology of each component.